The Phase I Sentinel Safety Cohort will assess the safety of AZD5156 (a combination of 2 mAbs, AZD1061 [cilgavimab, a component of the established therapy AZD7442] and AZD3152) in healthy adults.The Phase III Main Cohort will assess the safety and neutralizing activity of AZD3152 in adults and adolescents 12 years of age or older (weighing at least 40 kg) with conditions causing immune impairment, who are less likely to mount an adequate protective immune response after vaccination and thus are at high risk of developing severe COVID 19 in approximately 20 countries.
The aim of this phase I/III study will be to evaluate the safety and neutralizing activity of AZD3152 compared with AZD7442 for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.